Publication: 3415

Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Study Update

Citation:: Bone Marrow Transplantation vol 55 p 127, abstr O120

Meeting Instance:: EBMT 2020
Year:: 2020
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3304

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen
Grants:

Corr. Author:
Authors:: Peter M Voorhees Jonathan L Kaufman Jacob Laubach Douglas W Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J Costa Larry D Jr Anderson Nitya Nathwani Nina Shah Yvonne A Efebera Caitlin Costello Andrzej Jakubowiak Tanya M Wildes Robert Z Orlowski Kenneth H Shain Andrew J Cowan Sean Murphy Yana Lutska Huiling Pei Jon Ukropec Jessica Vermeulen Carla de Boer Daniela Hoehn Thomas S Lin Paul G Richardson

Networks:

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: